Evidence map›Paper›PMID 25378349›Full record

ArticleAnnals of the rheumatic diseases2016

TGFβ responsive tyrosine phosphatase promotes rheumatoid synovial fibroblast invasiveness.

Stephanie M Stanford, German R Aleman Muench, Beatrix Bartok, Cristiano Sacchetti, William B Kiosses, Jay Sharma, Michael F Maestre, Massimo Bottini, Tomas Mustelin, David L Boyle and 2 more

Abstract read
In one paragraph

Article in Annals of the rheumatic diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. The Antitumor Efficacy ofBioMed research international · 2020
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Stephanie M StanfordDivision of Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
German R Aleman MuenchDivision of Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Beatrix BartokDivision of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, California, USA.
Cristiano SacchettiDivision of Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA Inflammatory and Infectious Disease Center, Sanford-Burnham Institute for Medical Research, La Jolla, California, USA.
William B KiossesMicroscopy Core, The Scripps Research Institute, La Jolla, California, USA.
Jay SharmaDivision of Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Michael F MaestreDivision of Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Massimo BottiniInflammatory and Infectious Disease Center, Sanford-Burnham Institute for Medical Research, La Jolla, California, USA Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
Tomas MustelinInflammatory and Infectious Disease Center, Sanford-Burnham Institute for Medical Research, La Jolla, California, USA.
David L BoyleDivision of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, California, USA.
Gary S FiresteinDivision of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, California, USA.
Nunzio BottiniDivision of Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
La Jolla Institute for Immunology · USSanford Burnham Prebys Medical Discovery Institute · USScripps Research Institute · USUniversity of Rome Tor Vergata · IT

Funding

San Diego Clinical and Translational Research InstituteUL1TR000100 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S · 2012 to 2015
$19.7M
PTPN22 AND AUTOIMMUNITYR01AI070544 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BOTTINI, NUNZIO · 2008 to 2019
$4.0M
Regulation of p38 and inflammation by MAPK kinasesR01AI070555 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S · 2006 to 2016
$3.8M
c-Jun N-terminal kinase and joint destruction in RAR01AR047825 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S · 2002 to 2012
$2.7M
c-Jun N-terminal kinase and joint destruction in RAR55AR047825 · NIAMS · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI FIRESTEIN, GARY STEVEN · 2001 to 2001
$100k
NCATS NIH HHS UL1 TR000100NCATS NIH HHS UL1TR000100NIAID NIH HHS AI070555NIAID NIH HHS R01 AI070544NIAID NIH HHS R01 AI070555NIAMS NIH HHS AR47825NIAMS NIH HHS R01 AR047825NIAMS NIH HHS R55 AR047825
6 · The paper itself

Abstract

objectiveIn rheumatoid arthritis (RA), fibroblast-like synoviocytes (FLS) that line joint synovial membranes aggressively invade the extracellular matrix, destroying cartilage and bone. As signal transduction in FLS is mediated through multiple pathways involving protein tyrosine phosphorylation, we sought to identify protein tyrosine phosphatases (PTPs) regulating the invasiveness of RA FLS. We describe that the transmembrane receptor PTPκ (RPTPκ), encoded by the transforming growth factor (TGF) β-target gene, PTPRK, promotes RA FLS invasiveness.

methodsGene expression was quantified by quantitative PCR. PTP knockdown was achieved using antisense oligonucleotides. FLS invasion and migration were assessed in transwell or spot assays. FLS spreading was assessed by immunofluorescence microscopy. Activation of signalling pathways was analysed by Western blotting of FLS lysates using phosphospecific antibodies. In vivo FLS invasiveness was assessed by intradermal implantation of FLS into nude mice. The RPTPκ substrate was identified by pull-down assays.

resultsPTPRK expression was higher in FLS from patients with RA versus patients with osteoarthritis, resulting from increased TGFB1 expression in RA FLS. RPTPκ knockdown impaired RA FLS spreading, migration, invasiveness and responsiveness to platelet-derived growth factor, tumour necrosis factor and interleukin 1 stimulation. Furthermore, RPTPκ deficiency impaired the in vivo invasiveness of RA FLS. Molecular analysis revealed that RPTPκ promoted RA FLS migration by dephosphorylation of the inhibitory residue Y527 of SRC.

conclusionsBy regulating phosphorylation of SRC, RPTPκ promotes the pathogenic action of RA FLS, mediating cross-activation of growth factor and inflammatory cytokine signalling by TGFβ in RA FLS.

Indexed as

AnimalsArthritis, RheumatoidCell MovementFibroblastsGene Expression Regulation, EnzymologicGene Knockdown TechniquesHeterograftsHumansMice, NudeProtein Tyrosine PhosphatasesReceptor-Like Protein Tyrosine Phosphatases, Class 2RNA, MessengerSynovial MembraneTransforming Growth Factor beta1Up-RegulationProtein Tyrosine PhosphatasesPTPRK protein, humanReceptor-Like Protein Tyrosine Phosphatases, Class 2RNA, MessengerTransforming Growth Factor beta1FibroblastsInflammationRheumatoid Arthritis

Identifiers

PMID25378349
PMCPMC4422771
OpenAlexW2048970089

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.